Opinion|Videos|October 14, 2024
Optimizing Ovarian Cancer Care: PARP Resistance, Management of Oligoprogression, and Adverse Event Mitigation
Panelists discuss strategies to address PARP inhibitor (PARPi) resistance in ovarian cancer, including emerging combinations like gotistobart + pembrolizumab from the PRESERVE-004 trial, insights from the SOPRANO trial on managing oligometastases or oligoprogression, and approaches to mitigate or manage common adverse events associated with PARPi maintenance therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please comment on PARP inhibitor (PARPi) resistance. Are there promising strategies to overcome this challenge?
- PRESERVE-004 gotistobart + pembrolizumab
- Others?
- What insights can be drawn from the SOPRANO trial findings regarding the management of oligometastases or oligoprogression in ovarian cancer?
- What adverse events are most commonly seen with PARPi maintenance therapy and how do you mitigate or manage these?
Advertisement
Related to this article
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The 19-year veteran of CU Anschutz will be the fourth director in the 41-year history of Colorado’s only NCI-designated comprehensive cancer center.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
PRV111 produced pathologic complete responses in 21 of 22 patients with noninvasive oral cancer or high-grade dysplasia.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
A randomized phase 2 trial of berzosertib plus carboplatin in pretreated mCRPC stopped for futility amid fewer responses and more high-grade toxicity than the control arm.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Plus R-CHOP Meets PFS End Point in Newly Diagnosed DLBCL
2
‘Our Impact Will Be Broad and Transformative’: Wells Messersmith, MD, Takes the Reins at CU Anschutz Cancer Center
3
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
4
Berzosertib Plus Carboplatin Fails to Improve Responses in Pretreated mCRPC
5